BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33194317)

  • 1. No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study.
    Ascierto PA; Marincola FM; Fox BA; Galon J
    Oncoimmunology; 2020 Oct; 9(1):1826132. PubMed ID: 33194317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
    Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Muşină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
    J Clin Oncol; 2020 Nov; 38(31):3638-3651. PubMed ID: 32897827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions.
    Pagès F; Taieb J; Laurent-Puig P; Galon J
    Oncoimmunology; 2020 Aug; 9(1):1812221. PubMed ID: 32939329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions.
    Lanzi A; Sinicrope FA; Benson AB; Galon J
    Oncoimmunology; 2020 Jul; 9(1):1796003. PubMed ID: 32934890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer.
    Mlecnik B; Lugli A; Bindea G; Marliot F; Bifulco C; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert CI; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang J; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Maby P; Majdi A; Hijazi A; El Sissy C; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; Vliet SVL; Knijn N; Mușină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Patel P; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.
    Sinicrope FA; Shi Q; Catteau A; Poage GM; Zemla TJ; Mlecnik B; Benson AB; Gill S; Goldberg RM; Kahlenberg MS; Nair SG; Shields AF; Smyrk TC; Galon J; Alberts SR
    JCO Precis Oncol; 2022 Aug; 6():e2200010. PubMed ID: 35952316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study.
    Mlecnik B; Torigoe T; Bindea G; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Hirohashi Y; Furuhata T; Takemasa I; Patel P; Vora H; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Yoshino T; Taniguchi H; Bifulco C; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert CI; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang J; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson E; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Marliot F; Fredriksen T; Buttard B; Lafontaine L; Maby P; Majdi A; Hijazi A; El Sissy C; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; Van de Water C; van Lent-van Vliet S; Knijn N; Mușină AM; Scripcariu DV; Marincola FM; Ascierto PA; Fox BA; Pagès F; Kawakami Y; Galon J
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
    Pagès F; Mlecnik B; Marliot F; Bindea G; Ou FS; Bifulco C; Lugli A; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Angelova M; Vasaturo A; Maby P; Church SE; Angell HK; Lafontaine L; Bruni D; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Meyers JP; Paustian C; Feng Z; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Mușină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Sargent DJ; Fox BA; Galon J
    Lancet; 2018 May; 391(10135):2128-2139. PubMed ID: 29754777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The consensus immunoscore: toward a new classification of colorectal cancer.
    Lanzi A; Pagès F; Lagorce-Pagès C; Galon J
    Oncoimmunology; 2020 Jul; 9(1):1789032. PubMed ID: 32934885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
    Pagès F; André T; Taieb J; Vernerey D; Henriques J; Borg C; Marliot F; Ben Jannet R; Louvet C; Mineur L; Bennouna J; Desrame J; Faroux R; Kirilovsky A; Duval A; Laurent-Puig P; Svrcek M; Hermitte F; Catteau A; Galon J; Emile JF
    Ann Oncol; 2020 Jul; 31(7):921-929. PubMed ID: 32294529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness and robustness of Immunoscore for personalized management of cancer patients.
    Marliot F; Pagès F; Galon J
    Oncoimmunology; 2020 Oct; 9(1):1832324. PubMed ID: 33194318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance].
    Saberzadeh-Ardestani B; Foster NR; Lee HE; Shi Q; Alberts SR; Smyrk TC; Sinicrope FA
    Ann Oncol; 2022 Nov; 33(11):1159-1167. PubMed ID: 35963480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patients.
    Baldin P; Van den Eynde M; Mlecnik B; Galon J
    Oncoimmunology; 2020 Oct; 9(1):1826133. PubMed ID: 33110705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of early-stage colon cancer with Immunoscore
    Yalcin S; Philip PA; Athanasiadis I; Bazarbashi S; Shamseddine A
    Future Oncol; 2022 Feb; 18(5):613-623. PubMed ID: 34904905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
    Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
    Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer.
    Sinicrope FA; Shi Q; Hermitte F; Zemla TJ; Mlecnik B; Benson AB; Gill S; Goldberg RM; Kahlenberg MS; Nair SG; Shields AF; Smyrk TC; Galon J; Alberts SR
    JNCI Cancer Spectr; 2020 Jun; 4(3):pkaa023. PubMed ID: 32455336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).
    Lee H; Sha D; Foster NR; Shi Q; Alberts SR; Smyrk TC; Sinicrope FA
    Ann Oncol; 2020 Apr; 31(4):487-494. PubMed ID: 32165096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principles of risk assessment in colon cancer: immunity is key.
    Hijazi A; Galon J
    Oncoimmunology; 2024; 13(1):2347441. PubMed ID: 38694625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer.
    Nassif EF; Thibault C; Oudard S; Galon J
    Oncoimmunology; 2021 Feb; 10(1):1888488. PubMed ID: 33659099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
    Basile D; Broudin C; Emile JF; Falcoz A; Pagès F; Mineur L; Bennouna J; Louvet C; Artru P; Fratte S; Ghiringhelli F; André T; Derangère V; Vernerey D; Taieb J; Svrcek M;
    Ann Oncol; 2022 Jun; 33(6):628-637. PubMed ID: 35306156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.